Breast Cancer: Palbociclib and Fulvestrant Combination

We are testing a combination of palbociclib and fulvestrant in women with advanced breast cancer who have not responded to prior treatments. The goal is to evaluate its effectiveness and safety for these patients.

Efficacy phase (II)No PlaceboStandard MedicinesOralOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Ibrance
Ibrance is a cancer medicine used with hormone therapy to treat certain types of advanced or spread breast cancer.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Palbociclib
Palbociclib is a substance that slows growth of certain breast cancer cells by blocking proteins that control cell division in advanced disease.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Istituto Di Candiolo Fondazione Del Piemonte Per Loncologia IRCCS
Oncologia
Airali, Italy
University Of Bari Aldo Moro
Oncologia Medica
Altamura, Italy
Centro Di Riferimento Oncologico Di Aviano
Oncologia
Aviano-Castello, Italy
Sponsor: Consorzio Oncotech
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.